Pediatric Rheumatology
S100 protein levels predict abatacept response in juvenile idiopathic arthritis
Lower levels of S100 proteins at baseline predict better treatment response with abatacept in patients with polyarticular-course juvenile idiopathic arthritis, according to data published in Arthritis Research & Therapy.
CRP-albumin ratio, neutrophil-lymphocyte ratio predict persistent JIA disease activity
It may be possible to forecast persistent disease activity in juvenile idiopathic arthritis using C-reactive protein-to-albumin ratio and neutrophil-to-lymphocyte ratio, according to data published in BMC Rheumatology.
B-Cell Targeted Therapies
Training the ‘inner voice to be kind’ critical for young patients with rheumatic diseases
ORLANDO, Fla. — Cognitive behavioral therapy can help children and adolescents with rheumatic diseases cope with the challenges of their condition, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.
‘We try not to limit them’: Striving for normalcy key for children with rheumatic diseases
ORLANDO, Fla. — Allowing children with rheumatic diseases the time and space to formulate their own thoughts on their condition can facilitate communication and help them live a normal life, according to a presenter.
‘Nobody else to see’: Families trek hundreds of miles for pediatric rheumatology visits
“Your foot is very swollen. Like, there’s definitely something really wrong with your foot.”
TRAQ score predicts readiness to transition from pediatric to adult rheumatology care
Pediatric rheumatology patients could be considered ready to transfer to adult care if they score greater than 4 on the Transition Readiness Assessment Questionnaire, according to data published in Rheumatology.
Match Day fills 61.5% of pediatric rheumatology fellowship slots, continuing decline
Pediatric rheumatology fellowship programs filled just 61.5% of available slots for 2024 in the National Resident Matching Program, while nearly all adult program slots were filled, according to the American College of Rheumatology.
Multiple recent FDA approvals in pediatric rheumatology overcome ‘delayed’ trials
SAN DIEGO — The recent approvals of belimumab, golimumab, tofacitinib, secukinumab and ustekinumab in children with rheumatic diseases, all within the past 4 years, have changed the landscape in pediatric rheumatology, noted a speaker here.
Transitioning pediatric patients to adult care an ‘ongoing, years-long process’
The overwhelming majority of rheumatology practices have no formal policy for transitioning pediatric patients to adult care, according to a presenter at the 2023 AWIR annual conference.